OCTOBER 1st - DECEMBER 31st (previous year in brackets)
- Net sales amounted to TSEK 291 (TSEK 219)
- Earnings before interest and taxes (EBIT) amounted to MSEK -7,9 (MSEK -7,8)
- Earnings per share after dilution at SEK -0,10 (SEK 0,09)
- Cash flow from operating activities amounted to TSEK -5 779 (TSEK -4 887)
- Liquid assets at the end of the period MSEK 20,5 ( MSEK 11,5)
- Equity ratio was 83 % (75 %)
JANUARY 1st - DECEMBER 31st (previous year in brackets)
- Net sales amounted to TSEK 1 198 (TSEK 653)
- Earnings before interest and taxes (EBIT) amounted to MSEK -24,3 (MSEK 11,0)
- Earnings per share after dilution at SEK -0,3 (SEK- 0,14)
- Cash flow from operating activities amounted to TSEK -23 569 (TSEK -8 353)
- Liquid assets at the end of the period MSEK 20,5 (MSEK 11,5)
- Equity ratio was 83 % (75 %)
SUMMARY OF EVENTS DURING FIRST QUARTER
- RLS Global's notified bodies perform quality audits (ISO 13485 and MDD) without remarks
- Karin Fischer hands in her resignation
- Convatec is taking over the agreements with Swedish customers
- ChloraSolv is now delivered to the Convatec central warehouse on a regular basis
- ChloraSolv is reimbursed in the Netherlands
SUMMARY OF EVENTS DURING SECOND QUARTER
- Annual General Meeting is held May 19
- RLS signs distribution contract for Middle East
- RLS introduces ChloraSolv for the animal segment in Scandinavia by signing distribution contract with Swevet
- ChloraSolv is approved for leg ulcers in Kuwait
SUMMARY OF EVENTS DURING THIRD QUARTER
- An article regarding ChloraSolv is published in Journal of Wound Care
- RLS Global strengthens its solvency by transforming a loan to share capital
SUMMARY OF EVENTS DURING FOURTH QUARTER
- Björn Larsson starts as CEO
- RLS carries out a new share issue (rights issue) and thereby raises SEK 26.8 million in cash and cash equivalents after issue costs
- The Swedish Medicines Agency approves RLS' application for a clinical study regarding pressure ulcers
- RLS takes part in the conference Wounds UK in Harrogate, England
SUMMARY OF EVENTS AFTER FOURTH QUARTER
- An extra General Meeting is held February 9, 2023
- Lars Johansson is elected as Chairman of the Board
- RLS visits Arab Health, a global health conference in the Middle East and performs on-site distributor meetings and training sessions
The Year-end Report Q4, 2022, is enclosed and is also available here. (https://rls.global/wp-content/uploads/2023/02/RLS_Global_Q4_2022_EN.pdf)
Publication
This information was submitted for publication through the agency of the below contact person, at 08.30 CET on Feb 28th 2023.